CLINICAL_TRIALS
trial_result
· 2019-08-26
Clinical Trial Update: Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) [Phase 3]
Summary
Phase 3 trial evaluating immunogenicity and safety of the VARIVAX PE34 process in children with varicella; results posted after completion.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Varicella | Phase 3 | Status: COMPLETED | Results posted: 2019-08-26